16 May 2016
Reporter: Tammy Facey
India grants Gilead Sciences patent for Sovaldi
Gilead Sciences has had its patent application for hepatitis C treatment Sovaldi (sofosbuvir) accepted in India.

The Indian Intellectual Property Office (IIPO) granted Gilead’s application for the patent on 7 May, after rejecting its initial application in January last year.

The IIPO initially rejected the application on the ground of evergreening, ruling that the mere discovery of a new form of a known substance, which does not result in the enhancement of the known efficacy of the substance, is not eligible for patent protection.

Gilead appealed against the decision and on 7 May the IIPO approved the formulation, describing the drug compound as novel and inventive.

Gilead faced opposition from the Initiative for Medicines, Access and Knowledge (I-MAK) over access to the drug in certain countries.

I-MAK claimed the treatment was too expensive. The recommended 12-week course of treatments costs $84,000 in the US, or $1,000 per pill.

But in India, Gilead is engaged in voluntary licensing programmes with 11 generic manufacturers.

As of 26 April, the cost of Sovaldi was $384 per bottle, or around $14 per pill, in India, according to the Asia Pacific Network of People Living with HIV.

A spokesperson for Gilead commented: “We welcome news that the [IIPO] of New Delhi has granted our patent application.”

The spokesperson added: “[Our current] licensing programme enables the manufacture and distribution of high-quality, low-cost versions of the company’s medicines for HIV, hepatitis B and hepatitis C.”

More Asia news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Spruson & Ferguson launches Melbourne trademark office
12 June 2017 | Melbourne | Reporter: Barney Dixon
Law firm Spruson & Ferguson has opened a boutique trademark office in Melbourne, Australia
IP Group invests in Australian innovation
07 June 2017 | Canberra | Reporter: Barney Dixon
UK-based intellectual property investment company IP Group has committed AUD 200 million (USD 151.1 million) to Australia’s Group of Eight coalition
China could establish appellate IP court
15 May 2017 | Chengdu | Reporter: Barney Dixon
The court would be modelled on the US Court of Appeals for the Federal Circuit and cover mainly technology-related issues
IPO Pakistan and SIPO agree to MOU
23 March 2017 | Islamabad | Reporter: Barney Dixon
The deal will ensure high levels of cooperation in patent examination
China dominates 2016 PCT applications
15 March 2017 | Geneva | Reporter: Mark Dugdale
Chinese companies are continuing their onward march in dominating patent applications, with ZTE Corporation ranking as the biggest filer of international applications in 2016
Apple hits Qualcomm in China
26 January 2017 | Beijing | Reporter: Barney Dixon
Smartphone maker Apple has taken Qualcomm to court in China following the filing of its near $1 billion lawsuit in the US...
IP5 PPH programme extended
20 January 2017 | Beijing | Reporter: Barney Dixon
The IP5 Patent Prosecution Highway (PPH) programme has been extended for a further three years...